We have compiled the week's top news for you at
Market Access Today
!
-
ClearNote Health
has achieved a major milestone with the announcement of a new CPT code for its Avantect Ovarian Cancer Test, approved by the
American Medical Association
and set to take effect on October 1, 2024. This test, designed for patients at high risk of ovarian cancer, such as those with BRCA mutations or a family history, offers early detection, which can significantly improve survival rates. The
Centers for Medicare & Medicaid Services
has also proposed a reimbursement rate of $1,160 for the test, aligning it with the rate for the Avantect Pancreatic Cancer Test.
Dave Mullarkey
, CEO of ClearNote Health, emphasized the importance of early detection, as ovarian cancer is the most lethal gynecological cancer. This development marks a crucial step in expanding access to life-saving diagnostic tools for high-risk populations. (https://marketaccesstoday.com/clearnote-healths-avantect-ovarian-cancer-test-receives-cpt-code-and-preliminary-reimbursement-decision-from-cms/)
- The EU4Health Civil Society Alliance, consisting of over 16 health-focused organizations, including the
European Patients' Forum
, sent a letter to
European Commission
President
Ursula von der Leyen
on September 25, 2024, urging that health be prioritized in the next
European Commission
mandate. The Alliance's manifesto outlines 10 key priorities to secure health on the
European Union
political agenda and emphasizes the need for collaboration with civil society organizations to achieve ambitious health goals. The Alliance stresses that the next Commissioner for Health should continue to work closely with these organizations to develop inclusive and effective health policies that address the growing health challenges in Europe. (https://marketaccesstoday.com/health-focused-eu4health-civil-society-alliance-urges-prioritizing-health-in-next-european-commission-mandate/)
- The levonorgestrel-releasing intrauterine device, commonly known as Mirena by
Bayer
, has been highlighted for its effectiveness and safety in long-term contraception, with a failure rate of less than 1% and a lifespan of three to five years. The Korean Health and Medical Research Institute recently conducted a review that confirmed the LNG-IUD's safety, noting that initial side effects like spotting and irregular bleeding diminish over time. While concerns about weight gain, breast cancer, and depression have been raised, NECA emphasized that these concerns are not conclusive, calling for further research. This method is also used for treating heavy menstrual bleeding and dysmenorrhea, making it a versatile option for women seeking both contraception and therapeutic benefits. (https://marketaccesstoday.com/neca-confirms-intrauterine-device-as-a-safe-and-effective-long-term-contraceptive-option-with-manageable-side-effects/)
- The
NICE - National Institute for Health and Care Excellence
has recommended the combination of trifluridine–tipiracil (Lonsurf by
Taiho Pharmaceutical Co., Ltd.,
) and bevacizumab (Avastin by
Roche
and
Genentech
) for metastatic colorectal cancer patients who have undergone two prior treatments. This recommendation is based on clinical trial results from the SUNLIGHT Phase III study, which demonstrated improved progression-free survival and overall survival compared to trifluridine–tipiracil alone. The treatment is deemed cost-effective under
NHS
thresholds, with commercial access schemes in place to ensure affordability. Laurie Turner of the
NATIONAL NIEMANN-PICK DISEASE FOUNDATION
welcomed this new treatment option as a critical development for patients with limited alternatives. (https://marketaccesstoday.com/new-hope-for-metastatic-colorectal-cancer-patients-trifluridine-tipiracil-with-bevacizumab-recommended-by-nice/)
- The
NICE - National Institute for Health and Care Excellence
and the
NIHR (National Institute for Health and Care Research)
have collaborated for over two decades, with NIHR (National Institute for Health and Care Research) investing £211 million in research to address evidence gaps identified by NICE - National Institute for Health and Care Excellence. This partnership includes a rolling funding call, which has allocated £29 million so far. A notable project, the OBS UK study, received £3.65 million to improve maternity care by addressing excessive bleeding during childbirth. Researchers can apply for funding and propose new research topics via the NIHR (National Institute for Health and Care Research) website, ensuring ongoing advancements in healthcare research. (https://marketaccesstoday.com/nice-and-nihr-strengthen-healthcare-research-with-long-term-collaboration/)
Don't forget to subscribe to our newsletter!
